The ascendancy of Viagra and its effect on the medicinal landscape presents a intricate question for investors. While the initial sales figures were impressive, the exclusivity has expired, leading to a deluge of copycat alternatives that are eroding earnings. Moreover, the market is facing difficulties related to population trends and evolving hea